Pediatric Reactive Airway Disease Medication
- Author: Eric S Chin, MD; Chief Editor: Richard G Bachur, MD more...
Medication Summary
The goals of pharmacotherapy are to reduce morbidity and to prevent complications.
Beta2-Adrenergic Agonist Agents, Inhaled
Class Summary
These agents relieve reversible bronchospasm by relaxing smooth muscles of the bronchi. Systemic beta-agonists allow systemic delivery of medication to the pulmonary system in medical conditions where bronchoconstriction may inhibit delivery of medication to desired site because of little to no air movement. Oral administration is less effective than inhaled beta-adrenergic agonists, and has therefore fallen into disfavor. Does not appear to alter admission.
Salmeterol is a highly selective, long-acting beta2-adrenergic agonist with bronchodilatory activity. Salmeterol's benzene moiety resembles the structure of catecholamines, and occupies the active site of beta2-adrenergic receptor, while the long, lipophilic side chain of salmeterol, binds to the so-called exosite near the beta2-receptors. The binding at the exosite allows the active portion of the molecule to remain at the receptor site and continually engage and disengage with the receptor, therefore providing a long duration of action. This agent stimulates intracellular adenyl cyclase to catalyze the conversion of adenosine triphosphate to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels result in relaxation of bronchiolar smooth muscle, bronchodilation, and increased bronchial airflow.
Salmeterol (Serevent Diskus)
Long-acting beta2-agonist. Not for emergent use since onset is 30 min or more. By relaxing the smooth muscles of the bronchioles in conditions associated with bronchitis, emphysema, asthma, or bronchiectasis, can relieve bronchospasms. Effect may also facilitate expectoration.
Adverse effects are more likely to occur when administered at high or more frequent doses than recommended. Available as a dry powder for inhalation in 50 mcg blister packs.
Albuterol (Ventolin HFA, Proventil HFA)
Beta-agonist for bronchospasm refractory to epinephrine. Relaxes bronchial smooth muscle by action on beta2-receptors with little effect on cardiac muscle contractility. May decrease mediator release from mast cells and basophils and inhibit airway microvascular leakage. MDI delivers 90 mcg/actuation.
Continuous therapy may reduce need for mechanical ventilation.
Levalbuterol (Xopenex)
Used for treatment or prevention of bronchospasm. A selective beta2-agonist agent. Albuterol is a racemic mixture, while levalbuterol contains only the active R-enantiomer of albuterol. The S-enantiomer does not bind to beta2-receptors but may be responsible for some adverse effects of racemic albuterol, including bronchial hyperreactivity and reduced pulmonary function during prolonged use.
Anticholinergic Agents
Class Summary
These agents decrease muscle tone in the small and large pulmonary airways.
Ipratropium (Atrovent)
A quaternary ammonium anticholinergic bronchodilator acting at muscarinic receptors of the parasympathetic nervous system. Chemically related to atropine. Has antisecretory properties and, when applied locally, inhibits secretions from serous and seromucous glands lining the nasal mucosa.
Synergistic with beta2-agonists. Each actuation delivers 17 mcg. Solution for nebulization available as 0.02% (500 mcg/vial).
Beta2-Adrenergic Agonist Agents, Injection
Class Summary
These agents act to decrease the muscle tone in the small and large pulmonary airways.
Epinephrine (Adrenalin)
Elicits alpha-agonist effects that include increased peripheral vascular resistance, reversed peripheral vasodilatation, systemic hypotension, and vascular permeability. Beta2-agonist effects include bronchodilatation, chronotropic cardiac activity, and positive inotropic effects.
Terbutaline (Brethine)
Acts directly on beta2-receptors to relax bronchial smooth muscle, relieving bronchospasm and reducing airway resistance.
Methylxanthines
Class Summary
These agents provide bronchodilation at the cellular level. The exact mechanism is unknown (eg, alteration of intracellular calcium, inhibition of phosphodiesterase, and/or antagonism of prostaglandins). Routine addition to beta-agonist provides benefit in ED management. May be of benefit in impending respiratory failure.
Theophylline, 85% (Aminophylline)
Potentiates exogenous catecholamines, stimulates endogenous catecholamine release and diaphragmatic muscular relaxation, which, in turn, stimulates bronchodilation.
For bronchodilation, near toxic (>20 mg/dL) levels are usually required.
No role in acute asthma exacerbation.
Considered in children who are responding poorly on maximal therapy.
Magnesium Salt
Class Summary
These agents decrease acetylcholine release at the neuromuscular junction and may decrease resting tone of smooth muscle.
Magnesium sulfate
Thought to produce bronchodilation through counteraction of calcium-mediated smooth muscle constriction.
Gas Mixture
Class Summary
This agent is a blend of oxygen and helium that is less dense than air.
Helium and oxygen (Heliox)
Reduces airway resistance in bronchi with turbulent flow because of low density. Decreases the work of breathing, hence, delaying the onset of respiratory muscle fatigue, allowing other therapies to work.
Available in mixtures of 80:20 (helium:oxygen), 70:30, and 60:40.
General Anesthetic
Class Summary
Nonbarbiturate anesthetic/analgesic agent. An induction agent for airway management in patients with status asthmaticus and has a brief bronchodilatory effect.
Ketamine (Ketalar)
Acts on the cortex and limbic system, decreasing bronchospasm.
Mast Cell Stabilizers
Class Summary
These agents inhibit degranulation of sensitized mast cells following exposure to specific antigens.
Cromolyn (Intal)
Inhibits histamine release and slow-reacting substance of anaphylaxis from mast cell. MDI delivers 800 mcg/actuation. Solution for nebulization available as 20 mg/2 mL
Leukotriene Inhibitors
Class Summary
These agents inhibit the synthesis of leukotriene.
Zileuton (Zyflo)
Effective in aspirin-induced, cold air, and exercise-induced asthma. Not for use in acute episodes of asthma. Prophylactic use only.
Hepatic transaminase levels should be evaluated before initiation. Contraindicated in patients with active liver disease.
Zafirlukast (Accolate)
Cysteinyl leukotriene-receptor antagonist. Inhibits aspirin-induced, cold air, and exercise-induced asthma.
Not for use in acute episodes of asthma.
Montelukast (Singulair)
Cysteinyl leukotriene-receptor antagonist. Inhibits aspirin-induced, cold air, and exercise-induced asthma. Not for use in acute episodes of asthma.
Corticosteroid
Class Summary
These agents have anti-inflammatory properties and cause profound and varied metabolic effects. They modify the body's immune response to diverse stimuli. Oral prednisone should never be substituted for an inhaled corticosteroid in children with a severe acute asthma exacerbation.
Frequent use of inhaled corticosteroid therapy is associated with less ED visits and less hospitalizations. Current research has not proven any long-term adverse effects with children receiving long-term inhaled corticosteroid.
Dexamethasone (Decadron)
Has many pharmacologic benefits but significant adverse effects. Stabilizes cell and lysosomal membranes, increases surfactant synthesis, increases serum vitamin A concentration, inhibits prostaglandin and proinflammatory cytokines (eg, TNF-alpha, IL-6, IL-2, and IFN-gamma). The inhibition of chemotactic factors and factors that increase capillary permeability inhibits recruitment of inflammatory cells into affected areas. Suppresses lymphocyte proliferation through direct cytolysis and inhibits mitosis. Breaks down granulocyte aggregates, and improves pulmonary microcirculation. Has multiple glucocorticoid and mineralocorticoid effects.
Readily absorbed via the GI tract and metabolized in the liver. Inactive metabolites are excreted via the kidneys. Lacks salt-retaining property of hydrocortisone.
Patients can be switched from an IV to PO regimen in a 1:1 ratio.
Prednisolone (Orapred, Prelone, Pediapred)
Glucocorticosteroid that occurs naturally and synthetically. Used for both acute and chronic asthma. May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.
Loading or initial dose should be taken all at once in the am; may suppress natural cortisone production; hence, requires tapering the dose upon discontinuation.
As soon as the dose for relief is found, a maintenance dose may be established until the nonsteroidal drugs are effective; must always use a decreasing dose to avoid serious renal suppression.
In seasonal allergy a "booster" of prednisone may speed resolution of symptoms. Quite effective in "exhaustion" stage of seasonal allergy.
Prednisone (Sterapred)
May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.
Methylprednisolone (Medrol, Solu-Medrol)
For treatment of inflammatory and allergic reactions. By reversing increased capillary permeability and suppressing PMN activity, may decrease inflammation. Allows reduction of ongoing airway inflammation. May increase responsiveness to beta2-agonists by increasing the number of beta2-adrenergic receptors. Prophylactic inhaled steroids in those diagnosed with asthma may impede airway remodeling, bronchial hyperreactivity, and future airway damage.
Systemic adverse effects rarely occur with inhaled corticosteroids. Systemic response time is the same in IV and PO.
Steroid use is recommended if minimal improvement occurs after first beta2-agonist treatment, the patient was recently discontinued from steroids, the patient reports a history of asthma symptoms for a few days before presentation, or URI-associated symptoms are present.
Budesonide inhaled (Pulmicort Flexhaler, Pulmicort Respules)
Inhibits bronchoconstriction mechanisms, produces direct smooth muscle relaxation, may decrease number and activity of inflammatory cells, in turn decreasing airway hyperresponsiveness. Has extremely potent vasoconstrictive and anti-inflammatory activity. Alters level of inflammation in airways by inhibiting multiple types of inflammatory cells and decreasing production of cytokines and other mediators. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability.
Available as powder for inhalation in 90 mcg/actuation (actuation delivers ~80 mcg) or 180 mcg/actuation (actuation delivers ~160 mcg). Also available as suspension for nebulized inhalation in 0.25-mg/2 mL, 0.5-mg/2 mL, and 1-mg/2 mL. Indicated for maintenance treatment of asthma and prophylactic therapy.
H2 Receptor Antagonists
Class Summary
The combination of H1 and H2 antagonists may be useful in anaphylaxis not responding to H1 antagonists alone.
Cimetidine (Tagamet)
If no response to H1 antagonist alone, coadministration with this H2 antagonist treats itching and flushing in anaphylaxis, pruritus, urticaria, and contact dermatitis.
Monoclonal Antibody
Class Summary
May be considered in patients with severe asthma caused by allergens and unresponsive to other treatments.
Omalizumab (Xolair)
Recombinant, DNA-derived, humanized IgG monoclonal antibody that binds selectively to human IgE on surface of mast cells and basophils. Reduces mediator release, which promotes allergic response. Indicated for moderate-to-severe persistent asthma in patients who react to perennial allergens in whom symptoms are not controlled by inhaled corticosteroids.
[Guideline] Expert panel commissioned by the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee(CC), coordinated by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. The Expert Panel Report 3 (EPR-3) Full Report 2007: Guidelines for the Diagnosis and Management of Asthma. August 28, 2007;[Full Text].
[Guideline] Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/european Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. Jul 1 2009;180(1):59-99. [Medline].
Szefler SJ. Advances in pediatric asthma in 2007. J Allergy Clin Immunol. Mar 2008;121(3):614-9. [Medline].
Sahib El-Radhi A, Patel S. The clinical course of childhood asthma in association with fever. Clin Pediatr (Phila). Jul 2009;48(6):627-31. [Medline].
Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med. May 8 1997;336(19):1356-63. [Medline].
Litonjua AA, Carey VJ, Burge HA, et al. Exposure to cockroach allergen in the home is associated with incident doctor-diagnosed asthma and recurrent wheezing. J Allergy Clin Immunol. Jan 2001;107(1):41-7. [Medline].
Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. Oct 2000;162(4 Pt 1):1403-6. [Medline]. [Full Text].
Kim KW, Shin YH, Lee KE, Kim ES, Sohn MH, Kim KE. Relationship between adipokines and manifestations of childhood asthma. Pediatr Allergy Immunol. Sep 2008;19(6):535-40. [Medline].
Federico MJ, Wamboldt FS, Carter R, Mansell A, Wamboldt MZ. History of serious asthma exacerbations should be included in guidelines of asthma severity. J Allergy Clin Immunol. Jan 2007;119(1):50-6. [Medline].
Stewart LJ. Pediatric asthma. Prim Care. Mar 2008;35(1):25-40, vi. [Medline].
Hederos CA, Janson S, Andersson H, Hedlin G. Chest X-ray investigation in newly discovered asthma. Pediatr Allergy Immunol. Apr 2004;15(2):163-5. [Medline].
Hsu KH, Jenkins DE, Hsi BP, et al. Ventilatory functions of normal children and young adults--Mexican- American, white, and black. II. Wright peak flowmeter. J Pediatr. Aug 1979;95(2):192-6. [Medline].
Kaashmiri M, Shepard J, Goodman B, Lincourt WR, Trivedi R, Ellsworth A, et al. Repeat dosing of albuterol via metered-dose inhaler in infants with acute obstructive airway disease: a randomized controlled safety trial. Pediatr Emerg Care. Mar 2010;26(3):197-202. [Medline].
Morse RB, Hall M, Fieldston ES, McGwire G, Anspacher M, Sills MR, et al. Hospital-level compliance with asthma care quality measures at children's hospitals and subsequent asthma-related outcomes. JAMA. Oct 5 2011;306(13):1454-60. [Medline].
Stanford R, et al. Comparative clinical and economic outcomes in children with asthma initiating eitherfluticasone propionate plus salmeterol or inhaled corticosteroids plus montelukast. Ann Allergy Asthma Immunol. Nov 2009;103(5):62. [Full Text].
Nino G, Grunstein MM. Current concepts on the use of glucocorticosteroids and beta-2-adrenoreceptor agonists to treat childhood asthma. Curr Opin Pediatr. Feb 15 2010;[Medline].
Childhood Asthma Treatment: Not One-Size-Fits-All. National Heart, Lung, and Blood Institute (NHLBI); March 2,2010. [Full Text].
Massanari M, Milgrom H, Pollard S, Maykut RJ, Kianifard F, Fowler-Taylor A, et al. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma. Clin Pediatr (Phila). Oct 2009;48(8):859-65. [Medline].
Sandstrom T. Omalizumab in the management of patients with allergic (IgE-mediated) asthma. Journal of Asthma and Allergy. May 2009;2:49-62. [Full Text].
Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. Dec 2009;124(6):1210-6. [Medline].
Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair). US Department of Health and Human Services/FDA; July 2009. [Full Text].
Schramm CM, Carroll CL. Advances in treating acute asthma exacerbations in children. Curr Opin Pediatr. Jun 2009;21(3):326-32. [Medline].
Blackhall K, Appleton S, Cates CJ. Ionisers for chronic asthma. Cochrane Database Syst Rev. 2003;CD002986. [Medline]. [Full Text].
Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF Jr, et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med. Nov 24 2011;365(21):1990-2001. [Medline].
Mireku N, Wang Y, Ager J, Reddy RC, Baptist AP. Changes in weather and the effects on pediatric asthma exacerbations. Ann Allergy Asthma Immunol. Sep 2009;103(3):220-4. [Medline].
[Best Evidence] Sorkness CA, Lemanske RF Jr, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. Jan 2007;119(1):64-72. [Medline].
Li P, Guttmann A. Recent innovations to improve asthma outcomes in vulnerable children. Curr Opin Pediatr. Dec 2009;21(6):783-8. [Medline].
Amirav I, Newhouse MT. Metered-dose inhaler accessory devices in acute asthma: efficacy and comparison with nebulizers: a literature review. Arch Pediatr Adolesc Med. Sep 1997;151(9):876-82. [Medline].
Apter AJ, Szefler SJ. Advances in adult and pediatric asthma. J Allergy Clin Immunol. Mar 2004;113(3):407-14. [Medline].
Baren JM, Zorc JJ. Contemporary approach to the emergency department management of pediatric asthma. Emerg Med Clin North Am. Feb 2002;20(1):115-38. [Medline].
Beasley R, Crane J, Lai CK, Pearce N. Prevalence and etiology of asthma. J Allergy Clin Immunol. Feb 2000;105(2 Pt 2):S466-72. [Medline].
Becker A, Watson W, Ferguson A, et al. The Canadian asthma primary prevention study: outcomes at 2 years of age. J Allergy Clin Immunol. Apr 2004;113(4):650-6. [Medline].
Clainche LL, Timsit S, Rigourd V, et al. Asthma and the child below 5 years of age: diagnosis and treatment [in French]. Rev Mal Respir. Feb 2000;17(1 Pt 2):213-23. [Medline].
Craig VL, Bigos D, Brilli RJ. Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus. Pediatr Emerg Care. Feb 1996;12(1):1-5. [Medline].
Crain EF, Mortimer KM, Bauman LJ, et al. Pediatric asthma care in the emergency department: measuring the quality of history-taking and discharge planning. J Asthma. 1999;36(1):129-38. [Medline].
Csonka P, Mertsola J, Klaukka T, et al. Corticosteroid therapy and need for hospital care in wheezing preschool children. Eur J Clin Pharmacol. Nov 2000;56(8):591-6. [Medline].
Darr CD. Asthma and bronchiolitis. In: Emergency Medicine: Concepts and Clinical Practice. 4th ed. 1998:1137-45.
Eggleston PA, Wood RA, Rand C, et al. Removal of cockroach allergen from inner-city homes. J Allergy Clin Immunol. Oct 1999;104(4 Pt 1):842-6. [Medline].
Farber HJ, Johnson C, Beckerman RC. Young inner-city children visiting the emergency room (ER) for asthma: risk factors and chronic care behaviors. J Asthma. 1998;35(7):547-52. [Medline].
Garde Garde Jf, Haro E, Sanchez-Lucas C, Garde Noguera J. Antileukotrienes. Their use in pediatrics [in Spanish]. Allergol Immunopathol (Madr). May-Jun 2000;28(3):136-43. [Medline].
Gibbs MA, Camargo CA, Rowe BH, Silverman RA. State of the art: therapeutic controversies in severe acute asthma. Acad Emerg Med. Jul 2000;7(7):800-15. [Medline].
[Best Evidence] Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. May 11 2006;354(19):1985-97. [Medline]. [Full Text].
[Best Evidence] Hondras MA, Linde K, Jones AP. Manual therapy for asthma. Cochrane Database Syst Rev. Apr 18 2005;CD001002. [Medline]. [Full Text].
Kellner JD, Ohlsson A, Gadomski AM, Wang EE. Efficacy of bronchodilator therapy in bronchiolitis. A meta-analysis. Arch Pediatr Adolesc Med. Nov 1996;150(11):1166-72. [Medline].
Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr. Sep 1998;133(3):424-8. [Medline].
Kitch BT, Chew G, Burge HA, et al. Socioeconomic predictors of high allergen levels in homes in the greater Boston area. Environ Health Perspect. Apr 2000;108(4):301-7. [Medline].
Le Clainche L, Timsit S, Rigourd V, et al. Asthma in children below 5 years of age: diagnosis and treatment. Rev Mal Respir. Feb 1999;16(1):17-27. [Medline].
Newson T, McKenzie S. Cough and asthma in children. Pediatr Ann. Mar 1996;25(3):156-8, 161. [Medline].
Qureshi F, Zaritsky A, Lakkis H. Efficacy of nebulized ipratropium in severely asthmatic children. Ann Emerg Med. Feb 1997;29(2):205-11. [Medline].
Roback MG, Dreitlein DA. Chest radiograph in the evaluation of first time wheezing episodes: review of current clinical practice and efficacy. Pediatr Emerg Care. Jun 1998;14(3):181-4. [Medline].
Rubin BK, Albers GM. Use of anticholinergic bronchodilation in children. Am J Med. Jan 29 1996;100(1A):49S-53S. [Medline].
Rudolph CD. Supraesophageal complications of gastroesophageal reflux in children: challenges in diagnosis and treatment. Am J Med. Aug 18 2003;115 Suppl 3A:150S-156S. [Medline].
Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med. Nov 2005;23(7):842-7. [Medline].
Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med. Sep 7 2000;343(10):689-94. [Medline].
Spahn JD. Pharmacologic management of pediatric asthma. 1998;18 (1):165-81.
Stempel DA, Meyer JW, Stanford RH, Yancey SW. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol. Jan 2001;107(1):94-8. [Medline].
Steyer TE, Mallin R, Blair M. Pediatric asthma. Clinics in Family Practice. Jun 2003;5.
Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. Aug 3 2000;343(5):332-6. [Medline].
Sun HL, Chou MC, Lue KH, et al. The relationship of air pollution to ED visits for asthma differ between children and adults. Am J Emerg Med. Oct 2006;24(6):709-13. [Medline].
Walsh-Kelly CM, Kim MK, Hennes HM. Chest radiography in the initial episode of bronchospasm in children: can clinical variables predict pathologic findings?. Ann Emerg Med. Oct 1996;28(4):391-5. [Medline].
Welliver RC. Immunologic mechanisms of virus-induced wheezing and asthma. J Pediatr. Aug 1999;135(2 Pt 2):14-20. [Medline].
Werk LN, Steinbach S, Adams WG, Bauchner H. Beliefs about diagnosing asthma in young children. Pediatrics. Mar 2000;105(3 Pt 1):585-90. [Medline].
Williams JR, Bothner JP, Swanton RD. Delivery of albuterol in a pediatric emergency department. Pediatr Emerg Care. Aug 1996;12(4):263-7. [Medline].
Wohl ME, Majzoub JA. Asthma, steroids, and growth. N Engl J Med. Oct 12 2000;343(15):1113-4. [Medline]. [Full Text].
Wolfram RW. Asthma. In: The Clinical Practice of Emergency Medicine. 2nd ed. 1997:1093-96.
Zeffren BS, Windom HH, Bahna SL. Modern Treatment of Asthma in Children. Vol 43. Mosby Year Book; 1996:423-68.
| Height in Inches | Average Rate | Range* | Height in Inches | Average Rate | Range* |
| 40 | 150 | 110-190 | 56 | 330 | 240-420 |
| 41 | 160 | 115-205 | 57 | 340 | 240-420 |
| 42 | 170 | 120-220 | 58 | 360 | 260-460 |
| 43 | 180 | 130-220 | 59 | 375 | 270-480 |
| 44 | 190 | 135-245 | 60 | 390 | 280-500 |
| 45 | 200 | 145-255 | 61 | 400 | 290-510 |
| 46 | 210 | 150-270 | 62 | 415 | 300-530 |
| 47 | 220 | 160-280 | 63 | 430 | 310-550 |
| 48 | 230 | 165-295 | 64 | 445 | 320-570 |
| 49 | 240 | 175-305 | 65 | 460 | 330-590 |
| 50 | 250 | 180-320 | 66 | 480 | 345-615 |
| 51 | 260 | 190-330 | 67 | 500 | 360-640 |
| 52 | 270 | 195-345 | 68 | 515 | 370-660 |
| 53 | 280 | 200-360 | 69 | 530 | 380-680 |
| 54 | 300 | 215-385 | 70 | 550 | 395-705 |
| 55 | 315 | 225-405 | 71 | 570 | 410-730 |
| *Includes 95% of white males aged 7-20 years. Derived and adapted from J Pediatr 1979;95:192-6. | |||||
Print
